Andrea Cubitt
CEO & Co-Founder

The startup has developed an epigenetic testing platform that analyzes stress patterns and hormonal changes to predict and diagnose postpartum depression (PPD) before symptoms appear. By identifying at-risk individuals early, the platform enables healthcare providers to implement preventive care strategies during pregnancy or shortly after childbirth.
Raised to date
$3.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.